Abstract
Brain metastases (BM) are the most common brain tumor in adults and are a leading cause of cancer mortality. Metastatic lesions contain subclones derived from their primary lesion, yet their functional characterization is limited by a paucity of preclinical models accurately recapitulating the metastatic cascade, emphasizing the need for a novel approach to BM and their treatment. We identified a unique subset of stem-like cells from primary human patient brain metastases, termed brain metastasis-initiating cells (BMICs). We now establish a BMIC patient-derived xenotransplantation (PDXT) model as an investigative tool to comprehensively interrogate human BM. Using both in vitro and in vivo RNA interference screens of these BMIC models, we identified SPOCK1 and TWIST2 as essential BMIC regulators. SPOCK1 in particular is a novel regulator of BMIC self-renewal, modulating tumor initiation and metastasis from the lung to the brain. A prospective cohort of primary lung cancer specimens showed that SPOCK1 was overexpressed only in patients who ultimately developed BM. Protein–protein interaction network mapping between SPOCK1 and TWIST2 identified novel pathway interactors with significant prognostic value in lung cancer patients. Of these genes, INHBA, a TGF-β ligand found mutated in lung adenocarcinoma, showed reduced expression in BMICs with knockdown of SPOCK1. In conclusion, we have developed a useful preclinical model of BM, which has served to identify novel putative BMIC regulators, presenting potential therapeutic targets that block the metastatic process, and transform a uniformly fatal systemic disease into a locally controlled and eminently more treatable one.
Similar content being viewed by others
References
Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, Martinez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A et al (2013) SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One 8:e74250. doi:10.1371/journal.pone.0074250
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988. doi:10.1073/pnas.0530291100
Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX et al (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459:1005–1009. doi:10.1038/nature08021
Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT et al (2015) Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5:1164–1177. doi:10.1158/2159-8290.CD-15-0369
Brown KR, Otasek D, Ali M, McGuffin MJ, Xie W, Devani B et al (2009) NAViGaTOR: network analysis, visualization and graphing Toronto. Bioinformatics 25:3327–3329. doi:10.1093/bioinformatics/btp595
Cancer Genome Atlas Research N (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543–550. doi:10.1038/nature13385
Chen K, Huang YH, Chen JL (2013) Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin 34:732–740. doi:10.1038/aps.2013.27
Cousin E, Hannequin D, Ricard S, Mace S, Genin E, Chansac C et al (2003) A risk for early-onset Alzheimer’s disease associated with the APBB1 gene (FE65) intron 13 polymorphism. Neurosci Lett 342:5–8
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069–1075. doi:10.1038/nature07423
Du L, Wang H, He L, Zhang J, Ni B, Wang X et al (2008) CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 14:6751–6760. doi:10.1158/1078-0432.CCR-08-1034
Faltas B (2012) Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells. Front Oncol 2:68. doi:10.3389/fonc.2012.00068
Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang Z et al (2011) Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene 30:4707–4720. doi:10.1038/onc.2011.181
Friedman J, Hastie T, Tibshirani R (2010) Regularization paths for generalized linear models via coordinate descent. J Stat Softw 33:1–22
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751
Gobeil S, Zhu X, Doillon CJ, Green MR (2008) A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene. Genes Dev 22:2932–2940. doi:10.1101/gad.1714608
Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C et al (2007) Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446:765–770. doi:10.1038/nature05760
Gyorffy B, Surowiak P, Budczies J, Lanczky A (2013) Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 8:e82241. doi:10.1371/journal.pone.0082241
Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–549
Ketela T, Heisler LE, Brown KR, Ammar R, Kasimer D, Surendra A et al (2011) A comprehensive platform for highly multiplexed mammalian functional genetic screens. BMC Genom 12:213. doi:10.1186/1471-2164-12-213
Kittanakom S, Arnoldo A, Brown KR, Wallace I, Kunavisarut T, Torti D et al (2013) Miniature short hairpin RNA screens to characterize antiproliferative drugs. G3 (Bethesda) 3:1375–1387. doi:10.1534/g3.113.006437
Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9:302–312. doi:10.1038/nrc2627
Kotlyar M, Pastrello C, Sheahan N, Jurisica I (2016) Integrated interactions database: tissue-specific view of the human and model organism interactomes. Nucleic Acids Res 44:D536–D541. doi:10.1093/nar/gkv1115
Langley RR, Fidler IJ (2013) The biology of brain metastasis. Clin Chem 59:180–189. doi:10.1373/clinchem.2012.193342
Lee YS, Lee HH, Park J, Yoo EJ, Glackin CA, Choi YI et al (2003) Twist2, a novel ADD1/SREBP1c interacting protein, represses the transcriptional activity of ADD1/SREBP1c. Nucleic Acids Res 31:7165–7174
Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD et al (2010) Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 5:e14062. doi:10.1371/journal.pone.0014062
Li J, Sharkey CC, Huang D, King MR (2015) Nanobiotechnology for the therapeutic targeting of cancer cells in blood. Cell Mol Bioeng 8:137–150. doi:10.1007/s12195-015-0381-z
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715. doi:10.1016/j.cell.2008.03.027
Mao Y, Zhang N, Xu J, Ding Z, Zong R, Liu Z (2012) Significance of heterogeneous Twist2 expression in human breast cancers. PLoS One 7:e48178. doi:10.1371/journal.pone.0048178
Miao L, Wang Y, Xia H, Yao C, Cai H, Song Y (2013) SPOCK1 is a novel transforming growth factor-beta target gene that regulates lung cancer cell epithelial-mesenchymal transition. Biochem Biophys Res Commun 440:792–797. doi:10.1016/j.bbrc.2013.10.024
Mina LA, Sledge GW Jr (2011) Rethinking the metastatic cascade as a therapeutic target. Nature Rev Clin Oncol 8:325–332. doi:10.1038/nrclinonc.2011.59
Murakami M, Ohkuma M, Nakamura M (2008) Molecular mechanism of transforming growth factor-beta-mediated inhibition of growth arrest and differentiation in a myoblast cell line. Dev Growth Differ 50:121–130. doi:10.1111/j.1440-169X.2007.00982.x
Murugaesu N, Iravani M, van Weverwijk A, Ivetic A, Johnson DA, Antonopoulos A et al (2014) An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor. Cancer Discov 4:304–317. doi:10.1158/2159-8290.CD-13-0287
Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M et al (2009) WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138:51–62. doi:10.1016/j.cell.2009.04.030
Nolte SM, Venugopal C, McFarlane N, Morozova O, Hallett RM, O’Farrell E et al (2013) A cancer stem cell model for studying brain metastases from primary lung cancer. J Natl Cancer Inst 105:551–562. doi:10.1093/jnci/djt022
Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R et al (2012) Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Can Res 72:100–111. doi:10.1158/0008-5472.CAN-11-1403
Pastrana E, Silva-Vargas V, Doetsch F (2011) Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 8:486–498. doi:10.1016/j.stem.2011.04.007
Patchell RA (2003) The management of brain metastases. Cancer Treat Rev 29:533–540
Rahmathulla G, Toms SA, Weil RJ (2012) The molecular biology of brain metastasis. J Oncol 2012:723541. doi:10.1155/2012/723541
Royston P, Altman DG (2013) External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol 13:33. doi:10.1186/1471-2288-13-33
Saxena M, Christofori G (2013) Rebuilding cancer metastasis in the mouse. Mol Oncol 7:283–296. doi:10.1016/j.molonc.2013.02.009
Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG et al (2009) Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia 11:388–396
Shima Y, Kengaku M, Hirano T, Takeichi M, Uemura T (2004) Regulation of dendritic maintenance and growth by a mammalian 7-pass transmembrane cadherin. Dev Cell 7:205–216. doi:10.1016/j.devcel.2004.07.007
Shu YJ, Weng H, Ye YY, Hu YP, Bao RF, Cao Y et al (2015) SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway. Mol Cancer 14:12. doi:10.1186/s12943-014-0276-y
Singh M, Manoranjan B, Mahendram S, McFarlane N, Venugopal C, Singh SK (2014) Brain metastasis-initiating cells: survival of the fittest. Int J Mol Sci 15:9117–9133. doi:10.3390/ijms15059117
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al (2003) Identification of a cancer stem cell in human brain tumors. Can Res 63:5821–5828
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401. doi:10.1038/nature03128
Soffietti R, Ruda R, Mutani R (2002) Management of brain metastases. J Neurol 249:1357–1369. doi:10.1007/s00415-002-0870-6
Su B, Gao L, Baranowski C, Gillard B, Wang J, Ransom R et al (2014) A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer. PLoS One 9:e101411. doi:10.1371/journal.pone.0101411
Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM et al (2012) Patient-derived tumour xenografts as models for oncology drug development. Nature Rev Clin Oncol 9:338–350. doi:10.1038/nrclinonc.2012.61
Therneau TMG, Patricia M (2000) Modeling survival data: extending the Cox model. Statistics for biology and health, 1st edn. Springer, New York. doi:10.1007/978-1-4757-3294-8
Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X (2008) Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr J 55:11–21
Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ et al (2014) Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156:1002–1016. doi:10.1016/j.cell.2014.01.040
Venugopal C, Hallett R, Vora P, Manoranjan B, Mahendram S, Qazi MA et al (2015) Pyrvinium targets CD133 in human glioblastoma brain tumor-initiating cells. Clin Cancer Res 21:5324–5337. doi:10.1158/1078-0432.CCR-14-3147
Venugopal C, McFarlane NM, Nolte S, Manoranjan B, Singh SK (2012) Processing of primary brain tumor tissue for stem cell assays and flow sorting. J Vis Exp JoVE. doi:10.3791/4111
Waghorne C, Thomas M, Lagarde A, Kerbel RS, Breitman ML (1988) Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. Can Res 48:6109–6114
Wolf J, Muller-Decker K, Flechtenmacher C, Zhang F, Shahmoradgoli M, Mills GB et al (2014) An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation. Oncogene 33:4273–4278. doi:10.1038/onc.2013.515
Yang C, Fischer-Keso R, Schlechter T, Strobel P, Marx A, Hofmann I (2015) Plakophilin 1-deficient cells upregulate SPOCK1: implications for prostate cancer progression. Tumour Biol. doi:10.1007/s13277-015-3628-3
Yu F, Li G, Gao J, Sun Y, Liu P, Gao H et al (2016) SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance. Cell Prolif. doi:10.1111/cpr.12241
Zakaria N, Yusoff NM, Zakaria Z, Lim MN, Baharuddin PJ, Fakiruddin KS et al (2015) Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells. BMC Cancer 15:84. doi:10.1186/s12885-015-1086-3
Zhang C, Browne A, Child D, Divito JR, Stevenson JA, Tanzi RE (2010) Loss of function of ATXN1 increases amyloid beta-protein levels by potentiating beta-secretase processing of beta-amyloid precursor protein. J Biol Chem 285:8515–8526. doi:10.1074/jbc.M109.079079
Acknowledgements
This work was supported by funds from the Department of Surgery at McMaster University, Ontario Institute for Cancer Research Cancer Stem Cell Program, a Canadian Cancer Society Research Institute Innovation Grant and The Boris Family Fund for Brain Metastasis Research for Dr. Sheila Singh; Brain Canada PhD Studentship for Mohini Singh; Ontario Research Fund (GL2-01-030), McLaughlin Centre Accelerator grant (#MC-2013-05), Canada Research Chair Program (CRC #225404), and Canada Foundation for Innovation (CFI #12301, #203373, #29272, #225404, #30865) supported Dr. Igor Jurisica.
Author information
Authors and Affiliations
Contributions
Conceptualization and design: MS, CV, SS. Methodology: MS, CV, NM, SM, DB, PV, MQ, TV, MD, KD, AT. Data analysis and interpretation: MS, CV, TT, KB, RH, JM, IJ, DK, SS. Writing, review, and/or revision of the manuscript: MS, CV, NM, SM, DB, PV, MQ, BM, JM, IJ, DSS. Supervision, JAH, JM, IJ, SS
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no potential conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Singh, M., Venugopal, C., Tokar, T. et al. RNAi screen identifies essential regulators of human brain metastasis-initiating cells. Acta Neuropathol 134, 923–940 (2017). https://doi.org/10.1007/s00401-017-1757-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00401-017-1757-z